The challenge Novo Nordisk faces in China underscores a bigger shift in the Chinese biopharma industry.
Illustration by Sam Ward
Novo Nordisk is feeling good about China. In March, the pharmaceutical company behind the blockbuster diabetes-turned-weight loss drug Ozempic held its “Capital Markets Day” presentations and held a breakout session devoted to its strong showing and trajectory in China. As Maziar Mike Doustdar, head of international operations, put it “all of our competitors combined are not able to cover what we do.”
He had good reason to be cocky: Novo Nordisk’s sales of Ozempic in China doubl
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from David Barboza, Pulitzer Prize-winning former Shanghai correspondent for The New York Times.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
In recent years, there haven’t been any visible, large-scale demonstrations for Tibetan independence, either inside the country or abroad. This is a big contrast to the waves of self-immolations and solidarity protests of the past — and exactly what Beijing wants. If China’s digital surveillance and censorship efforts have reached their full potential in Tibet, what comes next?
The author of Mr. China discusses why improving knowledge of the country is so vital, why China has become so toxic politically and whether he would advise young people to make a career there today.
September 17th: Strategies for Identifying Military End Users
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
